This article was originally published in The Gray Sheet
Firm plans to spin out shares through a tax-free stock distribution of its newly created Celera Genomics business subject to shareholder and final board approval, the firm announces Sept. 23. Celera is an 80/20 joint venture between Perkin-Elmer and The Institute for Genomic Research which is mounting a private sector effort to sequence the human genome in three years
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.